A phase II study of the multitargeted kinase inhibitor lenvatinib in patients with advanced BRAF wild-type melanoma

Steven O'Day; Rene Gonzalez; Kevin Kim; Bartosz Chmielowski; Richard Kefford; Georgina Long; Carmen Loquai; Charles Lance Cowey; Axel Hauschild; John D. Hainsworth; Peter Hersey; Frances Boyle; T. R. Jeffry Evans; Omid Hamid; Nicole Meneses; Corina Andresen; Min Ren; James P. O'Brien; Keith Flaherty

doi:10.1200/jco.2013.31.15_suppl.9026

A phase II study of the multitargeted kinase inhibitor lenvatinib in patients with advanced BRAF wild-type melanoma

Steven O'Day, Rene Gonzalez, Kevin Kim, Bartosz Chmielowski, Richard Kefford, Georgina Long, Carmen Loquai, Charles Lance Cowey, Axel Hauschild, John D. Hainsworth, Peter Hersey, Frances Boyle, T. R. Jeffry Evans, Omid Hamid, Nicole Meneses, Corina Andresen, Min Ren, James P. O'Brien, Keith Flaherty

Faculty of Medicine, Health and Human Sciences

Research output: Contribution to journal › Meeting abstract

Original language	English
Pages (from-to)	9026-9026
Number of pages	1
Journal	Journal of Clinical Oncology
Volume	31
Issue number	15
DOIs	https://doi.org/10.1200/jco.2013.31.15_suppl.9026
Publication status	Published - 20 May 2013
Event	Annual Meeting of the American Society of Clinical Oncology (ASCO) - Chicago, United States Duration: 31 May 2013 → 4 Jun 2013

Access to Document

10.1200/jco.2013.31.15_suppl.9026

Cite this

O'Day, S., Gonzalez, R., Kim, K., Chmielowski, B., Kefford, R., Long, G., Loquai, C., Cowey, C. L., Hauschild, A., Hainsworth, J. D., Hersey, P., Boyle, F., Evans, T. R. J., Hamid, O., Meneses, N., Andresen, C., Ren, M., O'Brien, J. P., & Flaherty, K. (2013). A phase II study of the multitargeted kinase inhibitor lenvatinib in patients with advanced BRAF wild-type melanoma. Journal of Clinical Oncology, 31(15), 9026-9026. https://doi.org/10.1200/jco.2013.31.15_suppl.9026

@article{db3daf1c068b4ee1bbff85563b4a2b62,

title = "A phase II study of the multitargeted kinase inhibitor lenvatinib in patients with advanced BRAF wild-type melanoma",

author = "Steven O'Day and Rene Gonzalez and Kevin Kim and Bartosz Chmielowski and Richard Kefford and Georgina Long and Carmen Loquai and Cowey, {Charles Lance} and Axel Hauschild and Hainsworth, {John D.} and Peter Hersey and Frances Boyle and Evans, {T. R. Jeffry} and Omid Hamid and Nicole Meneses and Corina Andresen and Min Ren and O'Brien, {James P.} and Keith Flaherty",

year = "2013",

month = may,

day = "20",

doi = "10.1200/jco.2013.31.15_suppl.9026",

language = "English",

volume = "31",

pages = "9026--9026",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "15",

note = "Annual Meeting of the American Society of Clinical Oncology (ASCO) ; Conference date: 31-05-2013 Through 04-06-2013",

}

O'Day, S, Gonzalez, R, Kim, K, Chmielowski, B, Kefford, R, Long, G, Loquai, C, Cowey, CL, Hauschild, A, Hainsworth, JD, Hersey, P, Boyle, F, Evans, TRJ, Hamid, O, Meneses, N, Andresen, C, Ren, M, O'Brien, JP & Flaherty, K 2013, 'A phase II study of the multitargeted kinase inhibitor lenvatinib in patients with advanced BRAF wild-type melanoma', Journal of Clinical Oncology, vol. 31, no. 15, pp. 9026-9026. https://doi.org/10.1200/jco.2013.31.15_suppl.9026

TY - JOUR

T1 - A phase II study of the multitargeted kinase inhibitor lenvatinib in patients with advanced BRAF wild-type melanoma

AU - O'Day, Steven

AU - Gonzalez, Rene

AU - Kim, Kevin

AU - Chmielowski, Bartosz

AU - Kefford, Richard

AU - Long, Georgina

AU - Loquai, Carmen

AU - Cowey, Charles Lance

AU - Hauschild, Axel

AU - Hainsworth, John D.

AU - Hersey, Peter

AU - Boyle, Frances

AU - Evans, T. R. Jeffry

AU - Hamid, Omid

AU - Meneses, Nicole

AU - Andresen, Corina

AU - Ren, Min

AU - O'Brien, James P.

AU - Flaherty, Keith

PY - 2013/5/20

Y1 - 2013/5/20

U2 - 10.1200/jco.2013.31.15_suppl.9026

DO - 10.1200/jco.2013.31.15_suppl.9026

M3 - Meeting abstract

SN - 0732-183X

VL - 31

SP - 9026

EP - 9026

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 15

T2 - Annual Meeting of the American Society of Clinical Oncology (ASCO)

Y2 - 31 May 2013 through 4 June 2013

ER -